Bass PTAB challenge to Biogen patent fails
The USPTO’s Patent Trial and Appeal Board has refused to institute another inter partes review petition filed by Kyle Bass, this time against a Biogen patent for a method of treating multiple sclerosis
The Biogen petition is one of many filed by Bass’s Coalition for Affordable Drugs this year. In it, the Coalition cited three pieces of prior art and also an “admission of prior art” in the patent’s written description. It also...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.